

APR 20 2005

PATENT APPLICATION

Via Facsimile - (703) 872-9306  
MAIL STOP AMENDMENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Peter R. Baum and William C. Fanslow, III

Serial No.: 10/622,237

Group Art Unit No.: 1644

Filed: July 17, 2003

Examiner: M. Haddad

For: ANTIBODIES THAT BIND LDCAM (AS AMENDED)

Docket No.: 2873-USA

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.


In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/778,187 filed February 6, 2001. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

The above-cited list is submitted under § 1.97(c) and accompanied by the fee of \$180 as set forth in § 1.17(p). The Commissioner is authorized to charge the \$180 fee and any other fees which may be required to Deposit Account No. 09-0089. A duplicate copy of this sheet is enclosed.

Applicants request consideration of this information and passage of the application to issue.

Immunex Corporation  
Law Department  
1201 Amgen Court West  
Seattle, WA 98119-3105  
(206) 265-7000

Respectfully submitted,

  
James E. Klaniecki  
Attorney/Agent for Applicants  
Registration No.: 38,207  
Phone: (206) 265-7145

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Signed:   
Nanci M. Kertson

Date: April 20, 2005

APR 20 2005

Via Facsimile - (703) 872-9306  
MAIL STOP AMENDMENTPATENT APPLICATIONIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter R. Baum and William C. Fanslow, III

Serial No.: 10/622,237

Group Art Unit No.: 1644

Filed: July 17, 2003

Examiner: M. Haddad

For: ANTIBODIES THAT BIND LDCAM (AS AMENDED)

Docket No.: 2873-USA

INFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/778,187 filed February 6, 2001. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

The above-cited list is submitted under § 1.97(c) and accompanied by the fee of \$180 as set forth in § 1.17(p). The Commissioner is authorized to charge the \$180 fee and any other fees which may be required to Deposit Account No. 09-0089. A duplicate copy of this sheet is enclosed.

Applicants request consideration of this information and passage of the application to issue.

Respectfully submitted,

Immunex Corporation  
Law Department  
1201 Amgen Court West  
Seattle, WA 98119-3105  
(206) 265-7000  
James E. Klaniecki  
Attorney/Agent for Applicants  
Registration No.: 38,207  
Phone: (206) 265-7145CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Signed: 

Nand M. Kertson

Date: April 20, 2005

BEST AVAILABLE COPY

VIA Facsimile - (703) 872-9306  
Mail Stop Amendment

Sheet 1 of 2

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO. <b>2873-USA</b>	SERIAL NO. <b>10/622,237</b>
	APPLICANT <b>Peter R. Baum and William C. Fanslow III</b>			
	FILING DATE <b>July 17, 2003</b>		GROUP <b>1644</b>	

## U.S. PATENT DOCUMENTS

EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	6,512,095	01.28.03	Baum			
	A2	US-2002/0198147	12.2002	Baker et al.			
	A3	6,642,360	11.2003	Filvaroff et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	WO99/28462	06/10/99	PCT			
	B2	WO99/57132	11/11/99	PCT			
	B3	WO00/29435	05/25/00	PCT			
	B4	WO00/32776	06/08/00	PCT			
	B5	WO01/00237A1	01/04/01	PCT			
	B6	WO01/54477A2	08/02/01	PCT			
	B7	WO02/26930A2	04/04/02	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Attwood, T. "The bable of bioinformatics," <i>Science</i> , 290:47-49, 2000.
	C2	Bost, K.L. and Pascual, D.W., "Antibodies against a peptide sequence within the HIV envelope protein crossreacts with human interleukin-2," <i>Immunol. Invest.</i> , 17(6-7):577-586, 1988.
	C3	Gomyo, H. et al., "A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene <i>IGSF4</i> in the LOH region of chromosome 11q23.2," <i>Genomics</i> , 62:139-146, 1999.
	C4	Greene, J.L. et al., "Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cells costimulatory interactions," <i>J. Biol. Chem.</i> , 271(6):26762-26771, 1996.
	C5	Linsley, P.S. et al., "Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4)," <i>J. Biol. Chem.</i> , 270(25):15417-15424, 1995.
	C6	Metzler et al., "Solution structure of human CLTA-4 and delineation of a CD80/CD86 binding site conserved in CD28," <i>Nature Structural Biol.</i> , 4:527-531, 1997.
	C7	Skolnick et al. "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech.</i> , 18(1):34-39, 2000.
	C8	Strausberg, R., Genebank, Accession No. AA493561, August 28, 1997.

EXAMINER

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

VIA Facsimile - (703) 872-9306  
Mail Stop Amendment

Sheet 2 of 2

<b>Form PTO-1449</b>		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK		ATTORNEY DOCKET NO. 2873-USA	SERIAL NO. 10/622,237
OFFICE				APPLICANT Peter R. Baum and William C. Fanslow III	
INFORMATION DISCLOSURE CITATION				FILED DATE July 17, 2003	GROUP 1644
(Supplemental Sheet)					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	C9	The RIKEN Genome Exploration Research Group Phase II Team and the FANTOM Consortium; "Functional annotation of a full-length mouse cDNA collection," <i>Nature</i> 409:685-690, 2001			
	C10	Urase K., et al., Expression of TRA175 mRNA, a new member of the immunoglobulin superfamily, in developing mouse brain," <i>NeuroReport</i> 12(15):3217-3221, Oct. 2001			
	C11	Wakayama T., et al., "Cloning and Characterization of a Novel Mouse Immunoglobulin Superfamily Gene Expressed in Early Spermatogenic Cells," <i>Molecular Reproduction and Development</i> 60:158- 164, 2001			
EXAMINER			DATE CONSIDERED		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

BEST AVAILABLE COPY